# PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)

> **NCT00274638** · PHASE4 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 805 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Telmisartan & Hydrochlorothiazide
- **DRUG:** Losartan & Hydrochlorothiazide
- **PROCEDURE:** ABPM

## Key facts

- **NCT ID:** NCT00274638
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2003-07
- **Final completion:** —
- **Target enrollment:** 805 (ACTUAL)
- **Last updated:** 2013-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00274638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00274638, "PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00274638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*